Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?

Masafumi Nakamura | Yoshihiro Miyasaka | Yoshihiko Sadakari | Kenjiro Date | Takao Ohtsuka

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Correspondence
Masafumi Nakamura, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Email: mnaka@surg1.med.kyushu-u.ac.jp

Abstract
Management of intraductal papillary mucinous neoplasm is controversial, and several guidelines have aimed to establish an adequate strategy for surgical resection and surveillance. We compared various intraductal papillary mucinous neoplasm guidelines and considered new matters that are pivotal for improved treatment of intraductal papillary mucinous neoplasm. We identified and compared 11 published guidelines, three of which were major guidelines that mainly referred to the diagnosis and treatment of intraductal papillary mucinous neoplasm (International Association of Pancreatology 2012 guidelines, European Study Group on Cystic Tumours of the Pancreas 2013 guidelines, and American Gastroenterological Association 2015 guidelines). The main concerns of these three guidelines were indication for surgery and follow up of non-resected lesions. Among the differences between the three guidelines, the period of surveillance recommended was the most controversial matter. Meanwhile, several nomograms have been proposed to improve the diagnosis of intraductal papillary mucinous neoplasm from the level of experts’ experiences to that of rational systems. We discuss the adequate strategy of surveillance for intraductal papillary mucinous neoplasm with and without pancreatectomy and nomograms aiming to predict the risk of malignancy in patients with intraductal papillary mucinous neoplasm.

KEYWORDS
guideline, intraductal papillary mucinous neoplasm, nomogram, pancreatic ductal adenocarcinoma, surveillance

1 | INTRODUCTION

Intraductal papillary mucinous neoplasm (IPMN) is a macroscopic precursor lesion of pancreatic cancer and is usually incidentally found during abdominal screening of other diseases. IPMN may progress to colloid carcinoma and tubular carcinoma and accounts for 20% to 30% of pancreatic cancer.1–4 IPMN comprises main duct type (MD-IPMN), branch duct type (BD-IPMN), and mixed type (MD + BD). MD-IPMN more frequently progresses to malignant lesions (60-70%)2,5–7 than BD-IPMN.2,5,8 Although BD-IPMN is more commonly seen than MD-IPMN,9,10 Researchers have also hypothesized that benign BD-IPMN...
may develop distinct pancreatic ductal adenocarcinoma (PDAC) synchronously or metachronously. The natural history and high incidence of BD-IPMN make its surveillance controversial. Hence, several guidelines have been developed with an aim to establish an adequate strategy for surgical resection and surveillance of IPMN. We identified 11 available guidelines and further compared three major guidelines of IPMN published by the International Association of Pancreatology in 2012 (IAP2012), European Study Group on Cystic Tumours of the Pancreas in 2013 (EURO), and American Gastroenterological Association in 2015 (AGA). We also herein present a discussion of new topics that are pivotal for the next step in improving the surveillance and treatment of IPMN.

2 | COMPARISON OF CURRENT GUIDELINES FOR IPMN

Table 1 shows 11 published guidelines concerning IPMN. Although they include other pancreatic lesions such as cystic neoplasms or pancreatic intraepithelial neoplasia, most of them focus mainly on management of IPMN. Among them, three guidelines deal with pathological issues (#1, #10, #11). An illustrated consensus (#1) proposed a pathological definition of IPMN for differentiation from pancreatic intraepithelial neoplasia. A revised classification system and recommendations (#10) used the two-tier grading system (low-grade/high-grade) instead of the three-tier grading system (low-grade/intermediate-grade/high-grade) proposed by the Armed Forces Institutes of Pathology. The Recommendation of Verona consensus meeting (#11) provided the principles of pathological evaluation and reporting of IPMN.

The American Society for Gastrointestinal Endoscopy guideline (#2) discussed the use of endoscopic modalities, such as endoscopic ultrasonography (EUS), EUS-guided fine-needle aspiration (EUS-FNA), and endoscopic retrograde cholangiopancreatography (ERCP), in differentiating IPMN from other cystic pancreatic lesions. In 2006, international consensus guidelines (the IAP2006) (#3) were the first comprehensive guidelines referring to the diagnosis, indications for resection, and surveillance of IPMN. The Society for Surgery of the Alimentary Tract Patient Care Guidelines (#4) provided general information on the categories, symptoms, diagnosis, and treatment of cystic neoplasms of the pancreas; however, these guidelines were unable to indicate either definite criteria for surgical resection or a surveillance strategy. The consensus statements of the International Cancer of the Pancreas Screening consortium summit (#6) proposed that IPMN was a potential target for early detection and treatment in individuals at high risk for pancreatic cancer. Italian consensus guidelines (#8) mainly focused on the diagnostic and follow-up strategies of pancreatic cystic neoplasms.

The remaining three guidelines (#5, #7, #9) are the current comprehensive guidelines citing diagnostic work-up, indications for surgery, surveillance after surgery, and surveillance of non-resected IPMN. In this section, we compare these three guidelines (Table 2). The IAP2012 (#5) and EURO (#7) guidelines are expert consensuses, whereas the AGA guidelines (#9) were established by an evidence-based approach using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework and the PICO (Patient problem or population, Intervention, Comparison and Outcome) format. However, the AGA guidelines noted that all evidence concerning the management of pancreatic cystic neoplasms was of very low quality because most of the available data were from retrospective case series.

Comparison of these three guidelines shows that the main concerns are indications for surgery and follow up of non-resected lesions. Because IPMN varies from low-grade dysplasia to invasive cancer, it is important to establish a reliable indication that can predict malignant lesions. In the IAP2012 guidelines, high-risk stigmata (obstructive jaundice, an enhanced nodule, and a main pancreatic duct (MPD) of ≥10 mm) are absolute indications for surgery. If worrisome features are recognized (cysts ≥3 cm, thickened cyst wall, MPD size 5-9 mm, non-enhancing nodules, caliber change of pancreatic duct with pancreatic atrophy, or lymphadenopathy), EUS is recommended. Surgery should be considered if a definite nodule, MPD involvement, or positive cytology is seen on EUS. In the EURO guidelines, absolute indications for surgery include a cyst diameter ≥4 cm, pancreas-related symptoms (jaundice, diabetes, or acute pancreatitis), mural nodules, and MPD >6 mm; relative indications are a rapid increase in size and an elevated serum CA19-9 concentration. In the AGA guidelines, indications for surgery are positive cytology on EUS-FNA which is carried out if at least two of three high-risk features are present (cyst ≥3 cm, dilated MPD, or solid component). Threshold of the AGA guidelines was set at a high level from the viewpoint of medical economics. Therefore, the AGA guidelines carry a higher risk of excluding resection of malignant lesions than the other two guidelines. Lekkerkerker et al. carried out a comparative analysis of the three guidelines using 75 cases of IPMN and reported that 12% of malignant lesions would have been overlooked with the AGA guidelines whereas none would have been missed with the IAP2012 or the Euro guidelines. In addition, Singh et al. analyzed 225 patients who underwent EUS-FNA for pancreatic cystic lesions and pointed out that the AGA guidelines would have missed 45% of malignant IPMN lesions.

In the IAP2012 guidelines, surveillance of non-resected IPMN depends on the size of the cyst (<1 cm: CT/MRI every 2-3 years; 1-2 cm: CT/MRI every 12 months in the first 2 years, then at longer intervals; 2-3 cm: EUS every 3-6 months, then at longer intervals alternating MRI with EUS; and >3 cm: close surveillance alternating MRI with EUS every 3-6 months). The IAP2012 guidelines do not indicate a definite period of surveillance, although they state that “there are no good long-term data to indicate whether surveillance can be safely discontinued after long-term stability.” In the EURO guidelines, surveillance of non-resected IPMN should be carried out every 6 months in the first year, and annual surveillance with MRI (or EUS) is recommended for the following 5 years. After the fifth year, surveillance is recommended every 6 months. The EURO guidelines also state that surveillance should be continued as long as the patient is fit for surgery. The AGA guidelines suggest that patients with non-resected IPMN should undergo surveillance with MRI at 1, 3, and
5 years and that surveillance can be discontinued if no significant change is recognized. The matter of termination of surveillance of non-resected IPMN will be discussed in another section.

The IAP2012 and EURO guidelines mention the method of IPMN resection. Both guidelines agree that oncological resection should be carried out if malignancy is suspected and that partial resection is preferred to total pancreatectomy in the treatment of multiple BD-IPMN. However, the guidelines disagree regarding the management of dysplasia at the margin of intraoperative frozen sections. In the IAP2012 guidelines, additional resection is recommended if high-grade dysplasia or invasive carcinoma is recognized at the margin, and the presence of low-/moderate-grade dysplasia does not require further treatment. The EURO guidelines recommend additional resection even if moderate-grade dysplasia is recognized at the margin.

Another point is surveillance after IPMN resection. For invasive IPMN, the IAP2012 and EURO guidelines recommend the same surveillance as carried out for pancreatic cancer. In contrast, the AGA guidelines suggest MRI surveillance every 2 years even after invasive IPMN. For noninvasive IPMN, the IAP2012 guidelines recommend repeat examinations at 2 and 5 years for new recurrences after resection, whereas they also suggest a 6-month interval, which is appropriate for surveillance considering the risk of PDAC development. The EURO guidelines recommend annual follow up for noninvasive IPMN. The AGA guidelines suggest MRI surveillance every 2 years after resection of high-grade IPMN, but they do not recommend routine surveillance after resection of pancreatic cysts without high-grade dysplasia or invasive malignancy. This matter will also be discussed later.

### 3 | PREDICTION OF MALIGNANT IPMN BY NOMOGRAM

Besides expert opinion-based guidelines, several efforts have been made to establish a nomogram as a more rational system with which to predict malignant IPMN, as listed in Table 3. Shimizu et al. first reported a nomogram for IPMN, which covered both MD-IPMN and BD-IPMN simultaneously. Jang et al. included the largest clinicopathological data set of 645 patients and focused exclusively on BD-IPMN. Correa-Gallego et al. and Attiyeh et al. devised two independent nomograms for MD-IPMN and BD-IPMN, respectively. In these three nomograms, which contain an independent nomogram exclusively for BD-IPMN, cyst size and existence of a solid component are common predictors of malignant lesions in BD-IPMN, and older age is also a predictor in two nomograms. Gemenetzis et al. included both MD-IPMN and BD-IPMN in a nomogram, and one of its factors predicting invasive cancer is the neutrophil-to-lymphocyte ratio, which has been reported to be a predictor of invasive cancer and poor prognosis in patients with various types of tumors.

These nomograms were validated by two methods: internal validation and external validation (Table 3). External evaluation of the nomogram is recommended because of objectivity and repeatability. Three studies assessed their nomograms by external validation, and one study used internal validation, and one used no validation. The concordance index and area under the curve derived from validation are used to estimate validity of the nomogram. External validation of the nomogram as established by Attiyeh
et al.26 demonstrated good discrimination power (concordance index in the training and validation sets was 0.82 and 0.81, respectively).

A nomogram that simultaneously covers both BD-IPMN and MD-IPMN is feasible and versatile because morphological classification is sometimes vague. However, validation results have demonstrated that nomograms limited to BD-IPMN are precise with good discrimination. The nomogram discrimination power depends on patient volume and accurate patient data. Therefore, in the near future, establishment of a more convenient and reliable nomogram with which to predict malignant IPMN with greater accumulation of clinical data is expected.

### 4 SURVEILLANCE AFTER RESECTION OF IPMN

The aim of surveillance after resection of IPMN is early detection of recurrence. “Recurrence” after resection of IPMN includes several situations: recurrence of associated carcinoma, development of a new IPMN lesion, and progression of unrected IPMN in the remnant pancreas. Besides these types of IPMN recurrence, PDAC distinct from IPMN may also develop in the remnant pancreas. In this section, recurrence of carcinoma derived from a resected IPMN is designated as a recurrent lesion, and newly developing or progressing IPMN and newly developing PDAC in the remnant pancreas are designated as remnant pancreatic lesions.

Recurrent lesions frequently develop and influence patient survival after resection of invasive IPMN. Disease-specific survival of patients with recurrent lesions remains low.35–38 Therefore, it is reasonable to carry out postoperative surveillance for invasive IPMN as done for PDAC. Besides recurrence of invasive IPMN, several investigators have reported recurrent lesions after resection of noninvasive IPMN.39–44 We also experienced peritoneal dissemination after resection of high-grade IPMN.7 Even after resection of noninvasive IPMN, especially high-grade IPMN, attention should be paid to the development of recurrent lesions.

Several follow-up studies have revealed frequent development of remnant pancreatic lesions after resection of IPMN41,45–50 (Table 4).

### TABLE 2 Comparison of the guidelines citing diagnostic work-up, indications for surgery, surveillance after surgery, and surveillance of non-resected IPMN

| International consensus guidelines 2012 (IAP2012)11 | European Experts Consensus Statement (EURO)12 | American Gastroenterological Association Institution Guideline (AGA)13 |
|------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Types of guideline | Consensus guidelines | Consensus guidelines | Evidence-based guidelines |
| Type of tumor/ neoplasm | IPMN and MCN | Cystic tumor of the pancreas | Asymptomatic neoplastic pancreatic cyst |
| Initial assessment | CT and/or MRI | CT and/or MRI | MRI |
| Radiological assessment | Recommended if worrisome features (cyst ≥3 cm, thickened cyst wall, MPD 5-9 mm, non-enhancing nodule, caliber change of MPD, lymphadenopathy) are present | EUS is useful for surgical indication, and EUS-FNA is useful for differential diagnosis | EUS-FNA is recommended if two or more high-risk features (cyst ≥3 cm, dilated MPD, solid component) are present |
| Indication for resection | High-risk stigmata (obstructive jaundice, enhanced nodule, MPD ≥10 mm) or worrisome features + significant EUS findings (definite nodule, MPD involvement, positive cytology) | Absolute indications (cyst ≥4 cm, symptoms, mural nodules, MPD ≥6 mm), relative indications (rapid size increase, serum CA19-9 elevation) | Two or more high-risk features + positive cytology in EUS-FNA |
| Surveillance of non-resected cases | <1 cm: CT/MRI every 2-3 years; 1-2 cm: CT/MRI every 12 months; 2-3 cm: EUS every 3-6 months; >3 cm: close surveillance alternating MRI with EUS every 3-6 months | Surveillance with MRI (or EUS) 1st year: every 6 months; 2nd-5th year: every 12 months; >5th year: every 6 months | 1st, 3rd, 5th year: MRI. No more surveillance if no significant change has been recognized |
| Surveillance of resected cases | Invasive IPMN: same surveillance as PDAC; noninvasive IPMN (without residual lesion): repeat examination at 2 and 5 years | Invasive IPMN: same surveillance as PDAC; noninvasive IPMN: MRI or EUS every 12 months | Cyst with invasive cancer or dysplasia: MRI every 2 years; cyst without high-grade dysplasia or malignancy: no routine surveillance |

CT, computed tomography; EUS, endoscopic ultrasonography; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; MPD, main pancreatic duct; MRI, magnetic resonance imaging; PDAC, pancreatic ductal adenocarcinoma.
He et al.\textsuperscript{46} reported that the 10-year incidences of new IPMN, new IPMN requiring surgery, and invasive carcinoma in the remnant pancreas after resection of noninvasive IPMN were 62%, 18%, and 38%, respectively. Hirono et al.\textsuperscript{41} documented 14 remnant pancreatic lesions in 257 patients who underwent IPMN resection. Among these 14 remnant pancreatic lesions, five (35.7%) developed more than 5 years after the initial operation. We reported that the 5- and 10-year cumulative incidences of high-risk lesions, including high-grade and invasive IPMN and PDAC, were 7.8% and 11.8%, respectively.\textsuperscript{48} These data indicate that long-term surveillance (as long as the patient is fit for surgery) is required to detect remnant pancreatic lesions.

Hirono et al.\textsuperscript{41} reported that a candidate risk factor for these remnant pancreatic lesions was dysplasia at the pancreatic cut margin, which included not only malignant lesions but also low-grade lesions. Pea et al.\textsuperscript{51} analyzed 260 noninvasive IPMN and concluded that a family history of pancreatic cancer and high-grade IPMN as the initial lesion were risk factors for malignant lesions in the remnant pancreas. Our analysis revealed that high-grade/invasive IPMN, MD-IPMN, and an IPMN located in the distal pancreas as the initial lesion were risk factors for development of high-grade/invasive IPMN in the remnant pancreas. Presence of concomitant PDAC as the initial lesion was a risk factor for development of PDAC in the remnant pancreas.\textsuperscript{48} It has been suggested that a postoperative surveillance strategy designed according to the degree of dysplasia may be reasonable for noninvasive IPMN, although surveillance of the remnant pancreas after resection of low-grade BD-IPMN is still necessary for metachronous development of PDAC.\textsuperscript{11}

**5 | SURVEILLANCE FOR IPMN WITHOUT PANCREATECTOMY**

Although several guidelines have provided recommendations regarding management of IPMN without pancreatectomy,\textsuperscript{11–13,19} an adequate surveillance protocol has not yet been established. Whereas BD-IPMN infrequently develop invasive carcinoma, the incidence of PDAC concomitant with BD-IPMN (4.5-8.3%) is reportedly higher.

| Author | Year (training/validation) | No. patients (training/validation) | Objective IPMN | Intended pathological grade | Selected variables\textsuperscript{a} | Validation | C-index (training/validation) | AUC (training/validation) |
|--------|---------------------------|----------------------------------|----------------|----------------------------|--------------------------------|------------|-----------------------------|-------------------------|
| Correa-Gallego et al.\textsuperscript{25} | 2013 | 123/123 | BD (\& Mix/MD) | High-grade dysplasia and invasive carcinoma | Solid component (Y/N) Lesion diameter (cm) Weight loss (Y/N) | Internal validation | 0.74/0.74 |
| Attiyeh et al.\textsuperscript{26} | 2016 | 402/172 | BD (\& Mix/MD) | High-grade dysplasia and invasive carcinoma | Solid component (Y/N) Lesion diameter (>3.0 cm) Age Gender male (Y/N) Symptomatic (Y/N) | External validation | 0.82/0.81 |
| Jang et al.\textsuperscript{8} | 2016 | 645/624 | BD | High-grade dysplasia and invasive carcinoma | Solid component (Y/N) Lesion diameter (cm) Age MPD diameter (mm) Serum CEA (ng/mL) Serum CA19-9 (U/mL) | External validation | 0.783/0.737 |
| Shimizu et al.\textsuperscript{27,28} | 2010 | 81/180 | All types of IPMN | High-grade dysplasia and invasive carcinoma | Size of nodules (mm) Type of lesion (MD-IPMN) Gender female (Y/N) Cytology | External validation | 0.903/0.760 |
| Gemenetzis et al.\textsuperscript{29} | 2016 | 272/- | All types of IPMN | Invasive carcinoma | Solid component (Y/N) Lesion diameter (cm) MPD dilatation >5 mm Jaundice (Y/N) NLR | No validation | 0.895/- |

\textsuperscript{a}Selected variables in two nomograms established by Correa-Gallego et al.\textsuperscript{25} and Attiyeh et al.\textsuperscript{26} are listed in the nomogram targeting BD-IPMN.

AUC, area under the curve; BD-IPMN, branch duct-type intraductal papillary mucinous neoplasm; C-index, concordance-index; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; MD-IPMN, main duct-type IPMN; Mix, MD + BD-IPMN; MPD, main pancreatic duct; NLR, neutrophil-to-lymphocyte ratio.
than that of malignant transformation of BD-IPMN (0.0–3.0%)\textsuperscript{52–55} (Table 5). Thus, attention should be paid not only to malignant transformation of IPMN itself, but also to the development of concomitant PDAC during surveillance for BD-IPMN. In addition, surveillance carried out at shorter intervals might be needed to detect concomitant PDAC because Uehara et al.\textsuperscript{54} reported that most concomitant PDAC were discovered at an advanced stage or in an unresectable condition during their surveillance of IPMN despite carrying out surveillance every 3–6 months.

Another important issue is how long the surveillance should be continued in terms of detecting PDAC concomitant with IPMN. The AGA guidelines suggest that patients without significant changes in their pancreatic cyst for 5 years can discontinue surveillance. However, in their long-term surveillance of BD-IPMN without pancreatectomy, Tanno et al.\textsuperscript{55} reported that the 5- and 10-year cumulative incidences of the development of PDAC distinct from BD-IPMN were 3.0% and 8.8%, respectively. These findings suggest that surveillance of IPMN should be continued for more than 5 years even when the IPMN shows no significant morphological change.

Considering the high incidence of IPMN, the estimated prevalence of which is approximately 26/100 000 and increases three- to fourfold in individuals older than 60 years,\textsuperscript{56,57} determination of patients at high risk of developing distinct PDAC is urgently needed. One possible risk factor is a family history of PDAC. Nehra et al.\textsuperscript{58} showed that concurrent PDAC in patients who underwent resection of IPMN were more commonly observed in those with than in those without a family history of PDAC (11.1% vs 2.9%, respectively; \(P = 0.02\)). Meanwhile, Mandai et al.\textsuperscript{59} showed that the frequency of concomitant PDAC in patients with BD-IPMN or mixed IPMN was significantly higher in patients with than in those without a family history; however, median age of the patients with a family history was significantly higher than in those without a family history. To exclude the influence of age, Mandai et al. carried out another comparison in which they limited the age of patients to \(\geq 70\) years and, as a result, the frequency of concomitant PDAC was not significantly different between these two groups.

Although several Japanese investigators\textsuperscript{2,53} have recommended carrying out surveillance every 6 months for detection of PDAC concomitant with IPMN, the diagnostic modality that should be included in this protocol remains unclear. Alternating CT and MRCP twice a year seems to be a popular protocol in Japan,\textsuperscript{60} but it often fails to diagnose resectable PDAC.\textsuperscript{61} Conversely, Kamata et al.\textsuperscript{53}

### TABLE 4 Reports of remnant pancreatic lesions

| Author                  | Year | No. total patients | No. noninvasive IPMN patients | Follow-up period | Remnant pancreatic lesion | Five- and 10-year cumulative incidences of remnant pancreatic lesions |
|-------------------------|------|--------------------|-------------------------------|-----------------|---------------------------|---------------------------------------------------------------------|
| Schnelldorfer et al.\textsuperscript{50} | 2008 | 208                | 145                           | 3.2 years\textsuperscript{a} | 11                        | 3                                                                      | NA                                                                  |
| Miller et al.\textsuperscript{47}          | 2011 | 243                | 243                           | 73 months\textsuperscript{a} | 31 (+ 38\textsuperscript{c}) | 4 (invasive IPMN)                                                    | NA                                                                  |
| Moriya & Traverso\textsuperscript{49}      | 2012 | 203                | 160                           | 40 months\textsuperscript{b} | 17 (+ 14\textsuperscript{b}) | 4                                                                      | NA                                                                  |
| He et al.\textsuperscript{46}              | 2013 | 130                | 130                           | 38 months\textsuperscript{b} | 22                        | 5 (invasive lesion)                                                  | 7% and 38%\textsuperscript{d}                                      |
| Frankel et al.\textsuperscript{45}         | 2013 | 192                | 192                           | 46 months\textsuperscript{b} | 40                        | 3                                                                      | NA                                                                  |
| Hirono et al.\textsuperscript{41}          | 2016 | 257                | 172                           | 53.5 months\textsuperscript{b} | 14                        | 12 (IPMN 7/PDAC 5)                                                  | NA                                                                  |
| Miyasaka et al.\textsuperscript{48}        | 2016 | 195                | 160                           | 47 months\textsuperscript{b} | 29                        | 13 (IPMN 6/PDAC 7)                                                  | 7.8% and 11.8%\textsuperscript{e}                                  |

\textsuperscript{a}Mean.  
\textsuperscript{b}Median.  
\textsuperscript{c}Residual lesions.  
\textsuperscript{d}Invasive cancer.  
\textsuperscript{e}High-risk lesions.

IPMN, intraductal papillary mucinous neoplasm; NA, not available; PDAC, pancreatic ductal adenocarcinoma.

### TABLE 5 Reports of surveillance of IPMN without pancreatectomy

| Author                  | Year | No. total patients | Follow-up period | No. patients with malignant lesions | No. patients with concomitant PDAC | Cumulative incidence of concomitant PDAC |
|-------------------------|------|--------------------|-----------------|-------------------------------------|-----------------------------------|------------------------------------------|
| Tanno et al.\textsuperscript{52} | 2008 | 82                 | 61 months\textsuperscript{b} | 1                                  | NA                                | NA                                       |
| Uehara et al.\textsuperscript{54} | 2008 | 60                 | 87 months\textsuperscript{a} | 2                                  | 5                                 | 5 years: 6.9%                           |
| Tanno et al.\textsuperscript{55} | 2010 | 89                 | 64 months\textsuperscript{b} | 0                                  | 4                                 | 5 years: 3.0%; 10 years: 8.8%            |
| Kamata et al.\textsuperscript{53} | 2014 | 102                | 42 months\textsuperscript{b} | 0                                  | 7                                 | 3 years: 4.0%; 5 years: 8.8%            |

\textsuperscript{a}Mean.  
\textsuperscript{b}Median.

IPMN, intraductal papillary mucinous neoplasm; NA, not available; PDAC, pancreatic ductal adenocarcinoma.
prospectively surveyed 167 patients with untreated IPMN using an EUS-based protocol and found seven metachronous developments of concomitant PDAC, all of which could be treated by resection. Moreover, the diagnostic ability of EUS to detect these resectable concomitant PDAC when carried out twice a year was superior to other imaging modalities such as percutaneous ultrasonography, CT, or MRI. However, EUS seems to be invasive, and the diagnostic ability of EUS to detect early-stage concomitant PDAC largely depends on the operator’s skill; thus, EUS cannot be carried out at the same level globally. Other Japanese investigators62,63 have demonstrated the important roles of pancreatic juice cytology under ERCP to diagnose stage 0 or I PDAC, although ERCP is still associated with a risk of pancreatitis and is therefore unsuitable for screening. Nevertheless, establishment of a surveillance protocol using an adequate combination of EUS/ERCP for high-risk patients would contribute to an increase in the number of patients who are diagnosed with resectable concomitant PDAC.

In summary, it might be important to carry out long-term surveillance at short intervals for more than 5 years as long as the patient is fit for surgery. A common protocol for IPMN with and without resection is alternate CT and MRCP (EUS) twice a year in Japan65; however, its ability to improve overall survival and its cost-effectiveness should be evaluated. Further investigation using a prospective protocol with a large number of patients is needed to clarify the precise incidence of concomitant PDAC distinct from IPMN, to establish the optimal interval and period of surveillance, and to determine the most reliable risk factors for concomitant PDAC.

**DISCLOSURE**

Conflict of Interest: Authors declare no conflicts of interest for this article.

**REFERENCES**

1. Kang MJ, Lee KB, Jang JY, et al. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN. Pancreas. 2013;42:1267–74.

2. Ohtsuka T, Kono H, Tanabe R, et al. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg. 2012;204:44–8.

3. Rezaei N, Barbon C, Zaki A, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford). 2016;18:236–46.

4. Yamada S, Fujii T, Shimoyama Y, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2014;21:2444–52.

5. Hackert T, Fritz S, Klaus M, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262:875–80; discussion 880–1.

6. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–85; discussion 685–7.

7. Tamura K, Ohtsuka T, Ideno N, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg. 2014;259:360–8.

8. Jang JY, Park T, Lee S, et al. Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2016 [Epub ahead of print].

9. Giometti R, Intini S, Brondani G, et al. Incidental pancreatic cysts on 3D turbo spin echo magnetic resonance cholangiopancreatography: prevalence and relation with clinical and imaging features. Abdom Imaging. 2011;36:196–205.

10. Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010;105:2079–84.

11. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–97.

12. Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45:703–11.

13. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee; American Gastroenterology Association American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22.

14. Adsay V, Mino-Kenudson M, Furukawa T, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: recommendations of Verona Consensus Meeting. Ann Surg. 2016;263:162–77.

15. Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39:1730–41.

16. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977–87.

17. Hruban RH, Pitman MB, Klimstra DS, editors. Intraductal neoplasms. In: AFIP Atlas of Tumor Pathology, Series 4: Tumors of the Pancreas. Washington: American Registry of Pathology, 2007:75–110.

18. Jacobson BC, Baron TH, Adler DG, et al. ASGE guideline: the role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc. 2005;61:363–70.

19. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.

20. SSAT patient care guidelines. Cystic neoplasms of the pancreas. J Gastrointest Surg. 2007;11:1225–7.

21. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.

22. Buscaini E, Pezzi R, Cannizzaro R, et al. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Dig Liver Dis. 2014;46:479–93.

23. Lekkerkerker SJ, Besselink MG, Busch OR, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–31.
24. Singh AD, Zeh HJ, Brand RE, et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc. 2016;83(1107–17):e2.

25. Correa-Gallego C, Do R, Lafemina J, et al. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol. 2013;20:4948–55.

26. Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M, et al. Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the Pancreatic Surgery Consortium. Ann Surg. 2016 [Epub ahead of print].

27. Shimizu Y, Kanemitsu Y, Sano T, Senda Y, Mizuno N, Yamako K. A nomogram for predicting the probability of carcinoma in patients with intraductal papillary-mucinous neoplasm. World J Surg. 2010;34:2922–8.

28. Shimizu Y, Yamae H, Maguchi H, et al. Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers. Pancreas. 2015;44:459–64.

29. Gemenetzis G, Bagante F, Griffin JF, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2016 [Epub ahead of print].

30. Arima K, Okabe H, Hashimoto D, et al. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: a report from the Pancreatic Surgery Consortium. Ann Surg. 2016 [Epub ahead of print].

31. Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M, et al. Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the Pancreatic Surgery Consortium. Ann Surg. 2016 [Epub ahead of print].

32. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil to lymphocyte ratio predicts malignant potential in intraductal papillary mucinous neoplasms. J Gastrointestinal Surg. 2015;19:2171–8.

33. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil to lymphocyte ratio predicts malignant potential in intraductal papillary mucinous neoplasms. J Gastrointestinal Surg. 2015;19:2171–8.

34. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in clinical gastrointestinal type. Surgery. 2010;147:812–22.

35. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251:470–6.

36. Sadakari Y, Ohuchida K, Nakata K, et al. Invasive carcinoma derived from the noninvasive type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery. 2010;147:812–7.

37. Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116:3369–77.

38. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011;253:968–74.

39. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500–7.

40. D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004;239:400–8.

41. Hirono S, Kawai M, Okada K, et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2016;160:306–17.

42. Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260:356–63.

43. Marchegiani G, Mino-Kenudson M, Fernone CR, et al. Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg. 2015;262:1108–14.

44. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788–97.

45. Frankel TL, LaFemina J, Bamboat ZM, et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford). 2013;15:814–21.

46. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65.

47. Miller JR, Meyer JE, Waters JA, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford). 2011;13:759–66.

48. Miyasaka Y, Ohtsuka T, Tamura K, et al. Predictive factors for the metachronous development of high-risk lesions in the remnant pancreas after partial pancreatectomy for intraductal papillary mucinous neoplasm. Ann Surg. 2016;263:1180–7.

49. Moriya T, Traverso W. Fate of the pancreatic remnant after resection for an intraductal papillary mucinous neoplasm: a longitudinal level II cohort study. Arch Surg. 2012;147:528–34.

50. Schnellendorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143:639–46.

51. Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2016 [Epub ahead of print].

52. Tanno S, Nakano Y, Nishikawa T, et al. Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut. 2008;57:339–43.

53. Kamata K, Kitano M, Kudo M, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2014;46:22–9.

54. Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal adenocarcinoma in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms of the pancreas without mural nodules: a population study. Pancreas. 2008;37:139–44.

55. Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. World J Gastrointest Surg. 2010;2:314–8.
58. Nehra D, Oyarvide VM, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012;12:358–63.

59. Mandai K, Uno K, Yasuda K. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas? Pancreas. 2014;43:917–21.

60. Ohtsuka T, Tanaka M. Postoperative surveillance of branch duct IPMN. In: Tanaka M, editor. Intraductal papillary mucinous neoplasm of the pancreas. Tokyo: Springer Japan, 2014; pp. 189–99.

61. Tamura K, Ohtsuka T, Ideno N, et al. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal papillary mucinous neoplasm: a case report. JOP 2013;14:450–3.

62. Ohtsuka T, Ideno N, Aso T, et al. Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci. 2013;20:356–61.

63. Iiboshi T, Hanada K, Fukuda T, Yonehara S, Sasaki T, Chayama K. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer: establishing a new method for the early detection of pancreatic carcinoma in situ. Pancreas. 2012;41:523–9.

How to cite this article: Nakamura M, Miyasaka Y, Sadakari Y, Date K, Ohtsuka T. Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?. Ann Gastroenteral Surg. 2017;1:90–98. https://doi.org/10.1002/ags3.12012